Related Experiment Video
Updated: Aug 10, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Superactive octapeptide somatostatin analogs containing tryptophan at position 1
Summary
New octapeptide analogs of somatostatin show significantly enhanced growth hormone inhibition in rats. The most potent analog demonstrated over 94 times the activity of somatostatin, suggesting potential clinical applications.
Area of Science:
- Endocrinology
- Medicinal Chemistry
- Pharmacology
Background:
- Somatostatin is a peptide hormone that regulates various physiological processes, including growth hormone release.
- Developing potent and stable somatostatin analogs is crucial for therapeutic applications.
Purpose of the Study:
- To synthesize and evaluate novel octapeptide analogs of somatostatin.
- To assess the in vivo inhibitory activity of these analogs on growth hormone release in rats.
Main Methods:
- Synthesis of a series of octapeptide analogs with modifications at N-terminus, hexapeptide sequence, and C-terminus.
- Purification of analogs using High-Performance Liquid Chromatography (HPLC).
- In vivo determination of growth hormone inhibitory activity in rats.
Main Results:
- Eight octapeptides with N-terminal tryptophan exhibited greater inhibitory effects than somatostatin.
- The analog D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2 was 94.3 times more potent than somatostatin.
- Specific structural features, such as N-terminal D-tryptophan and phenylalanine at position 3, enhanced activity.
Conclusions:
- Octapeptide analogs of somatostatin can be designed for significantly enhanced growth hormone inhibitory activity.
- The analog D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2 shows high potency and prolonged duration of action.
- These findings suggest potential clinical utility for these novel somatostatin analogs.
![Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)
Related Concept Videos
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...